Results 101 to 110 of about 14,165 (152)

CDK4/6 inhibitor rechallenge therapy in advanced breast cancer. [PDF]

Discov Oncol
Sun Y, Zhao Y, Yu X, Qi Y, Dai X.
europepmc   +1 more source

Epigenetic and fragment-based profiling across CDK4/6 inhibitors in first-line HR+/HER2- metastatic breast cancer. An ancillary analysis of the MAGNETIC.1 study. [PDF]

Breast
Noto C, Foffano L, Giudici F, Molteni E, Franzoni A, Tessitori M, Cucciniello L, Bolzonello S, Da Ros L, Bortot L, Scudeler E, Pastò B, Cudia G, Della Rossa S, Bonotto M, Minisini AM, Damante G, Belletti B, Gerratana L, Puglisi F.   +19 more
europepmc   +1 more source

Premenopausal Patients With Clinically Aggressive Metastatic Breast Cancer Successfully Treated With a First-Line Palbociclib-Containing Regimen: Two Cases and Literature Review. [PDF]

Cancer Rep (Hoboken)
Fu PA, Hsu YC, Hsu HP, Lin TC, Chung WP.
europepmc   +1 more source

Alternate actions of CDK4/6 inhibitors beyond cell cycle blockade: unexplored roles in therapy resistance. [PDF]

Cancer Metastasis Rev
Scordamaglia D, Talia M, Zicarelli A, Mondino AA, De Rosis S, Di Dio M, Silvestri F, Meliti C, Cirillo F, De Francesco EM, Malaguarnera R, Capalbo C, Maggiolini M, Lappano R.   +13 more
europepmc   +1 more source

WEE1 inhibition delays resistance to CDK4/6 inhibitor and antiestrogen treatment in ER+ MCF7 cells. [PDF]

NPJ Syst Biol Appl
He W, Demas DM, Kraikivski P, Shajahan-Haq AN, Baumann WT.   +4 more
europepmc   +1 more source

The Dual Effects of CDK4/6 Inhibitors on Tumor Immunity. [PDF]

Cancers (Basel)
Si Y, Li H, Shi Y.
europepmc   +1 more source

CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis. [PDF]

Nat Genet
Chan ICC, Zhang P, Pan X, Castro C, Fox N, Lewis AM, Weis K, Cuibus A, Tittley S, Petrone G, Beeler JS, Tran D, Mustion G, Fronick C, Stopsack KH, Cruchaga C, Abdel-Wahab O, Bolton KL.   +17 more
europepmc   +1 more source

Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer. [PDF]

Elife
Armand J, Kim S, Kim K, Son E, Kim M, Kalinsky K, Yang HW.   +6 more
europepmc   +1 more source

mTOR-driven autophagy suppression defines metabolic vulnerability in CDK4/6 inhibitor-resistant HR⁺/HER2^- breast cancer. [PDF]

Cell Death Dis
von Wichert L, Stroh A, Witt M, Wanzel M, Mernberger M, Griewing S, Wündisch T, Pfitzner BM, Teply-Szymanski J, Litmeyer AS, Denkert C, Wagner U, Stiewe T, Gremke N.   +13 more
europepmc   +1 more source